Recently, Guangzhou Enzyme Products Biotechnology Co., Ltd. (hereinafter referred to as “Enzyme Products”) has made another significant breakthrough in the field of peptide drugs. Following the completion of the filing of semaglutide API, the company’s biosynthesized semaglutide backbone has successfully passed the Drug Master File (DMF NUMBER ASSIGNED: 041076) filing with the U.S. Food and Drug Administration (FDA) . This achievement marks Enzyme Products’ access to the international regulatory system in the field of core raw materials for GLP-1 drugs, accelerating its global industrialization layout.
The finished enzyme products fully leverage the company’s comprehensive advantages in synthetic biology, artificial intelligence, engineering technology, separation technology, and green chemistry, combined with the company’s globally leading “Green Bio-manufacturing Platform,” achieving significant technological breakthroughs in numerous areas such as novel gene editing technology, specific enzyme modification technology, strain modification technology, high-density fermentation technology, bioconjugation technology, and the application of novel purification technologies . This series of innovative measures has not only enabled the Smegglutide series products to achieve orders-of-magnitude breakthroughs in production capacity and efficiency, but also ensured a significant improvement in their quality stability and economic viability.
In addition, an enzyme product active raw material production base has been established in Shaoguan, Guangdong Province. The project covers approximately 150 acres, with a planned construction area of 70,000 square meters and a total investment of approximately 1.1 billion yuan. It is planned to produce 1,000 tons of green active raw materials such as peptides, sugars, and nucleotides annually, including 2 tons of GLP-1 raw materials (such as smegglutide and telpolide), making it the largest biosynthetic GLP-1 raw material base in China . The establishment of this project in Shaoguan marks a leap in the company’s production capacity from hundreds of tons to thousands of tons, further consolidating the company’s leading position in the field of green active raw materials.
Regarding enzyme products
Enzyme Products is committed to becoming a global leader in green active ingredients, employing next-generation synthetic biology technology to focus on the green production of bioactive ingredients such as peptides, proteins, sugars, nucleic acids, and lipids. Leveraging over 20 years of research and industry experience accumulated by its founding team, the company has established a leading multidisciplinary technology platform in China. It has achieved large-scale production of dozens of green active ingredients, including Smegglutinin, S -Pros-Xylane, Ergothioneine, Ectoin, Collagen Tripeptide, Human Milk Oligosaccharides, Ceramides, NAD+, NMN, Copper Peptide, Carnosine, and Glutathione. It has cumulatively provided high-quality green active ingredients to over 2,000 well-known companies in the fields of functional skincare, biomedicine, nutrition and health, and animal nutrition .
The company ranks among the top international companies in terms of R&D investment, scale, and output value. It has undertaken a number of key provincial and municipal R&D projects, applied for nearly 200 invention patents, and received more than ten national and local titles, including National Specialized, Refined, and Innovative Small Giant Enterprise, National High-tech Enterprise, Guangdong Provincial Postdoctoral Innovation Practice Base, Shenzhen Peacock Team, Shenzhen Potential Unicorn Enterprise, Zhuhai Innovation and Entrepreneurship Team, and Gansu Provincial Specialized, Refined, and Innovative Small and Medium-sized Enterprise. It has also been recognized as one of the Top 20 High-Growth Enterprises in Shenzhen in 2024, the Harvard Business Review High-Energy Innovation Team Award in 2023, and one of the Top 100 High-Growth Enterprises in Shenzhen in 2022.